Download
s12885-021-08006-0.pdf 1,29MB
WeightNameValue
1000 Titel
  • Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors
1000 Autor/in
  1. Griewing, Luisa Maria |
  2. Schweizer, Claudia |
  3. Schubert, Philipp |
  4. Rutzner, Sandra |
  5. Eckstein, Markus |
  6. Frey, Benjamin |
  7. Haderlein, Marlen |
  8. Weissmann, Thomas |
  9. Semrau, Sabine |
  10. Gostian, Antoniu-Oreste |
  11. Müller, Sarina K. |
  12. Traxdorf, Maximilian |
  13. Iro, Heinrich |
  14. Zhou, Jian-Guo |
  15. Gaipl, Udo S. |
  16. Fietkau, Rainer |
  17. Hecht, Markus |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-03-24
1000 Erschienen in
1000 Quellenangabe
  • 21(1):314
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12885-021-08006-0 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992796/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Immune checkpoint inhibitors (ICI) have become standard treatment in different tumor entities. However, safe treatment with ICI targeting the PD-1/PD-L1 axis requires early detection of immune-related adverse events (irAE). There exist different questionnaires of drug manufacturers for the detection of irAE that have not been validated so far.!##!Methods!#!The prospective non-interventional ST-ICI trial studied treatment with PD-1/PD-L1 ICI alone or combined with radiotherapy. In the current analysis, the detection rate of self-reported irAE with a patient questionnaire containing 41 different questions was compared to clinician-reported irAE.!##!Results!#!Between April 2017 and August 2019, a total of 104 patients were prospectively enrolled. NSCLC (44%) and HNSCC (42%) were the most frequent tumor entities. A total of 784 questionnaires were collected. A total of 29 irAE were reported by clinicians. The most frequent irAE was hypothyroidism (9%), followed by skin reactions (5%), hepatitis (4%), diarrhea (3%), and pneumonitis (3%). Questions that became significantly more often positive at time points of clinician-reported irAE were 'weight change', 'difficulty to grip things', 'bloody or mucous stool' and 'insomnia'. Self-reported organ-specific questions detected at least 50% of clinician-reported irAE of gastrointestinal, lung, endocrine, and skin irAE. It was not possible to detect hepatic irAE with the questionnaire.!##!Conclusion!#!Questionnaires can help to detect gastrointestinal, lung, endocrine, or skin irAE, but not hepatic irAE. Questions on 'weight change' and 'insomnia' may help to increase the detection rate of irAE, besides organ-specific questions. These results are a valuable contribution to the future development of a specific and practicable questionnaire for early self-reported detection of irAE during ICI therapy in cancer patients.!##!Trial registration!#!ClinicalTrials.gov, NCT03453892 . Registered on 05 March 2018.
1000 Sacherschließung
lokal PD-L1
lokal Aged [MeSH]
lokal Questionnaire
lokal Hypothyroidism/immunology [MeSH]
lokal Pneumonia/chemically induced [MeSH]
lokal Solid tumors
lokal Self Report/statistics
lokal Pneumonia/immunology [MeSH]
lokal Programmed Cell Death 1 Receptor/antagonists
lokal Drug Monitoring/statistics
lokal Drug Eruptions/diagnosis [MeSH]
lokal Male [MeSH]
lokal Hepatitis/immunology [MeSH]
lokal Immune Checkpoint Inhibitors/adverse effects [MeSH]
lokal Neoplasms/therapy [MeSH]
lokal Toxicity
lokal Programmed Cell Death 1 Receptor/immunology [MeSH]
lokal Diarrhea/epidemiology [MeSH]
lokal Pneumonia/diagnosis [MeSH]
lokal Chemoradiotherapy/adverse effects [MeSH]
lokal Pneumonia/epidemiology [MeSH]
lokal Research Article
lokal Diarrhea/immunology [MeSH]
lokal Drug Eruptions/immunology [MeSH]
lokal Female [MeSH]
lokal B7-H1 Antigen/immunology [MeSH]
lokal Drug Eruptions/epidemiology [MeSH]
lokal Drug Monitoring/methods [MeSH]
lokal Hepatitis/diagnosis [MeSH]
lokal Humans [MeSH]
lokal Neoplasms/immunology [MeSH]
lokal Prospective Studies [MeSH]
lokal Chemoradiotherapy/methods [MeSH]
lokal Hypothyroidism/epidemiology [MeSH]
lokal Hepatitis/epidemiology [MeSH]
lokal Middle Aged [MeSH]
lokal Immune checkpoint inhibitors
lokal PD-1
lokal Hypothyroidism/chemically induced [MeSH]
lokal Diarrhea/chemically induced [MeSH]
lokal Diarrhea/diagnosis [MeSH]
lokal B7-H1 Antigen/antagonists
lokal Hypothyroidism/diagnosis [MeSH]
lokal Patient-reported irAE
lokal Immune-related adverse events
lokal Side effects
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/R3JpZXdpbmcsIEx1aXNhIE1hcmlh|https://frl.publisso.de/adhoc/uri/U2Nod2VpemVyLCBDbGF1ZGlh|https://frl.publisso.de/adhoc/uri/U2NodWJlcnQsIFBoaWxpcHA=|https://frl.publisso.de/adhoc/uri/UnV0em5lciwgU2FuZHJh|https://frl.publisso.de/adhoc/uri/RWNrc3RlaW4sIE1hcmt1cw==|https://frl.publisso.de/adhoc/uri/RnJleSwgQmVuamFtaW4=|https://frl.publisso.de/adhoc/uri/SGFkZXJsZWluLCBNYXJsZW4=|https://frl.publisso.de/adhoc/uri/V2Vpc3NtYW5uLCBUaG9tYXM=|https://frl.publisso.de/adhoc/uri/U2VtcmF1LCBTYWJpbmU=|https://frl.publisso.de/adhoc/uri/R29zdGlhbiwgQW50b25pdS1PcmVzdGU=|https://frl.publisso.de/adhoc/uri/TcO8bGxlciwgU2FyaW5hIEsu|https://frl.publisso.de/adhoc/uri/VHJheGRvcmYsIE1heGltaWxpYW4=|https://frl.publisso.de/adhoc/uri/SXJvLCBIZWlucmljaA==|https://frl.publisso.de/adhoc/uri/WmhvdSwgSmlhbi1HdW8=|https://frl.publisso.de/adhoc/uri/R2FpcGwsIFVkbyBTLg==|https://frl.publisso.de/adhoc/uri/RmlldGthdSwgUmFpbmVy|https://frl.publisso.de/adhoc/uri/SGVjaHQsIE1hcmt1cw==
1000 Hinweis
  • DeepGreen-ID: 04ec999fc16d42f3a24270e2d2b312f5 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6462815.rdf
1000 Erstellt am 2023-11-15T14:43:23.220+0100
1000 Erstellt von 322
1000 beschreibt frl:6462815
1000 Zuletzt bearbeitet 2023-11-30T20:30:16.941+0100
1000 Objekt bearb. Thu Nov 30 20:30:16 CET 2023
1000 Vgl. frl:6462815
1000 Oai Id
  1. oai:frl.publisso.de:frl:6462815 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source